导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.97% | 1774/4773 |
| 近一周 | -1.62% | 593/5462 |
| 近一月 | -1.24% | 888/5421 |
| 近一季 | -3.89% | 1493/5209 |
| 近半年 | -9.64% | 3526/4920 |
| 近一年 | 5.52% | 1585/4366 |
| 近两年 | 32.90% | 2161/2954 |
| 近三年 | 23.10% | 1362/2253 |
| 成立以来 | 84.83% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.67% 683/4961 |
1.90% 2981/5312 |
- - |
- - |
| 2025 | 7.51% 2924/4813 |
-4.54% 3193/3635 |
1.13% 2454/4076 |
7.69% 3440/4524 |
3.41% 679/4813 |
| 2024 | 19.93% 494/3463 |
9.70% 121/2808 |
2.19% 381/3014 |
7.85% 2798/3129 |
-0.80% 1522/3463 |
| 2023 | 7.22% 149/2656 |
16.67% 193/2280 |
1.11% 238/2385 |
-3.56% 952/2515 |
-5.76% 1490/2655 |
| 2022 | -12.97% 310/2207 |
-10.94% 459/1919 |
2.66% 1273/2016 |
-9.94% 328/2113 |
5.69% 449/2208 |
| 2021 | 29.95% 70/1822 |
3.11% 196/1255 |
4.05% 930/1330 |
19.25% 54/1466 |
1.57% 870/1822 |
| 2020 | 11.58% 823/1250 |
-9.12% 656/1028 |
-0.34% 1016/1067 |
10.72% 518/1164 |
11.26% 553/1184 |
| 2019 | - - |
- - |
- - |
- - |
-2.33% 903/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发央企创新ETF VS. 长安沪深300非周期A(740101) |